[VIRTUAL] Phase 1 safety, tolerability and pharmacokinetics of ACT-01, a neuroprotective small molecule for the disease modifying treatment of Acute Optic Neuritis and MS (ECTRIMS 2021) - Sep 23, 2021 - Abstract #P714; Pres time: Oct 14, 2021; 12:00 PM - 09:00 PM; Location: ePoster Library; "ACT-01 administered with 2h i.v. infusions of single doses up to 3.2 mg/Kg and of multiple doses up to 3.0 mg/Kg daily for up to 5 consecutive days was safe and well-tolerated. ACT-01 displayed linear pharmacokinetics with respect to C(max) and AUC and no significant accumulation occurred with multiple doses over 5 days"
Clinical • P1 data • PK/PD data • Ocular Inflammation • Ophthalmology • Optic Neuritis • GSK3B • MRI • NDRG1
|
|
Prof. Pablo Villoslada; M. Masso; S. Paris; S. Hutchings; A. Koch
|